Our findings suggest that liraglutide, through its targeting of GLP1Rs, affects the expression of ILK-related PI3K/AKT/PTEN, ultimately mitigating diabetic cardiomyopathy by regulating these signaling pathways. The gene discussed is PTEN; the disease is diabetic cardiomyopathy.